RJ Hamster
🌟 Homebuilder Earnings: D.R. Horton Sticks Out as Pulte…
Ticker Reports for April 27th
→ Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
(From Banyan Hill Publishing)
AI Insider Selling: Sales Hit Photronics, Credo & CoreWeave as Shares Spike
Insiders are making moves in three soaring artificial intelligence (AI) stocks, selling millions’ worth of shares. However, knowing which of these sales clearly signal negative indicators to investors and which do not requires a thorough analysis. Here’s what recent insider trades are signaling.
Phontronic’s Insider Sales Soar Alongside Shares
First up is a name that garnered significant attention near the end of 2025, Photronics (NASDAQ: PLAB). Photronics sells photomasks, key components in the semiconductor manufacturing process. The stock saw an over 45% single-day spike in December. This was the result of an impressive earnings report and the announcement of significant capital expenditures, indicating strong demand going forward. Photronics has continued to soar in 2026, already up more than 50% for the year.
However, as shares move up, Photronics has also seen a fair bit of insider selling in Q2. Overall, MarketBeat has tracked $14 million worth of selling during the quarter, a big-time shift from just $3.44 million in Q1.
Notably, none of these sales came under a predetermined 10b5-1 plan, indicating that they were discretionary in nature. Furthermore, many of these sales represented a significant portion of individual insider holdings. For example, insiders Hsueh-Chun Wang and Rui Zhang each reduced their holdings by 20% or more.
Given the significant appreciation seen in Photronics shares, these sales are a moderately bearish sign for the stock. Still, most insiders continue to hold large stakes in the company, suggesting that they maintain a solid degree of confidence going forward.
Credo Insiders Sell as Shares as Hit New Highs
Next up is Credo Technology Group (NASDAQ: CRDO), an AI stock that has experienced significant ups and downs over the recent past. The stock rose to nearly $190 in early December 2025, before falling to less than $100 by early March 2026. Within two months, Credo saw a significant recovery, rising above $190. In late April, Credo moved to all-time highs near $195. Much of this enthusiasm comes as Credo agreed to acquire DustPhotonics, adding more optical networking products to its primarily copper-based lineup.
As Credo shares surge to unprecedented levels, insiders are capitalizing, selling around $21 million worth of shares in Q2. Still, less than a month into Q2, this selling is largely consistent with Q1 selling. Over those full three months, sales came in near $53 million.
Additionally, the majority of Q2 sales came under 105b-1 plans or were relatively small as a percentage of individual holdings, making them not overly concerning. For example, despite making multiple sales, Chi Fung Cheng lowered total shares held by less than 2% and still holds over 6 million Credo shares.
Given these mitigating circumstances, Credo’s Q2 sales do not provide much of a negative signal.
CoreWeave’s Insider Sales Rise by More Than 3X in Q2
Last up is one of the AI trade’s most well-known newcomers, neo-cloud company CoreWeave (NASDAQ: CRWV). CoreWeave has also been a highly volatile stock since going public in March 2025. The stock moved up to over $180 in June 2025, before ending the year near $70. CoreWeave has seen a huge recovery in 2026, up almost 50% to around $107 per share.
Throughout its publicly traded history, CoreWeave has seen a very large amount of insider selling, at $6.55 billion. After a big drop in selling during Q1, insiders are stepping up their sales again. In April alone, MarketBeat has tracked more than $1.3 billion in sales, over three times higher than the $396 million in sales that took place in all of Q1.
Importantly, many of CoreWeave’s sales came under 105b-1 plans or had other mitigating factors. However, this is not true of one of CoreWeave’s largest insiders, hedge fund Magnetar Financial. Magnetar has sold hundreds of millions of dollars’ worth of CoreWeave shares in Q2. Despite big-time sales, Magnetar continues to indirectly hold billions of dollars’ worth of CoreWeave. Clearly, insiders are selling more as CoreWeave rises, a negative signal.
CoreWeave: Insiders Sell, Analysts Disagree
Among this group, CoreWeave’s insider selling activity is the most noteworthy. Notwithstanding recent selling, the huge value of trades around CoreWeave is a significant technical overhang on the stock. Magnetar has shown a consistent pattern of selling its shares, and the company still has massive exposure to CoreWeave. Due to this, the overhang is unlikely to abate soon.
Still, Wall Street analysts continue to take a generally bullish view on the stock. The MarketBeat consensus price target near $125 implies more than 15% upside in shares. The range of targets on CoreWeave is very wide. Targets updated in April stretch as high as $175 and as low as $67. These figures imply upside of more than 60% and downside of more than 35%, respectively, illustrating the large degree of uncertainty around this name.
Ad Banyan Hill Publishing
Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company👉 Unlock The Ticker Now And Get It Completely Free.
These 3 Psychedelic Stocks Activated After Trump’s Executive Order
The Trump administration’s April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile domestic political news stories, but the implications for this small but growing industry are tremendous. Indeed, within days, the FDA began to make moves, awarding national priority vouchers to select companies developing drugs in this category, thereby reducing drug review times considerably.
Single-session wins were to be expected for some of the bigger players in the psychedelics industry, and sure enough, share prices for several of these companies skyrocketed. As time goes on, though, it will be up to these drug developers to prove that they have the medicines to back up the newfound hype. These are some companies that may be worth watching.
A Promising Candidate Could Make It to Market Sooner, Preempting Financial Challenges
One of the biggest beneficiaries of the executive order was biotech firm Compass Pathways (NASDAQ: CMPS), which has seen its share price surge by nearly 80% in the last month. Specifically, the enthusiasm centers on its COMP360, a drug candidate for treatment-resistant depression and a recipient of a priority voucher.
For Compass, one challenge has been maintaining operational viability while developing a drug that appears to be quite promising. The company has faced mounting net losses in recent years, and losses per share have widened even as the weighted average basic shares outstanding have more than doubled in the last several years.
A shorter runway to commercialization for COMP360 could significantly help Compass overcome these hurdles. While the firm was already flagged as a Buy by several analysts, it received a wave of new bullish ratings and price targets immediately following the executive order. It heads into late April with eight out of 10 ratings as a Buy and over 100% in upside potential, even after its recent rally.
Another Speculative Penny Stock With a Promising Candidate
Another clinical-stage biotech with a potential psychedelic-based treatment for certain types of depression, AtaiBeckley (NASDAQ: ATAI) also saw a stock surge in mid-April. Though Phase 3 trials of its BPL-003 won’t begin until later in 2026, AtaiBeckley reported positive results from an earlier phase in April.
For its current sales—just $4 million annually—AtaiBeckley has a sky-high price-to-sales (P/S) ratio in the 400s, which would typically indicate that ATAI’s shares are massively overvalued. And in addition to being a pre-profit biotech name, the firm is also a penny stock, with shares priced below $5 even after the latest boost. That’s all to say that AtaiBeckley is a speculative investment, likely subject to volatility.
Still, the momentum behind psychedelic treatments for mental health disorders may help the company to bring BPL-003 to market sooner than initially expected, potentially. Ten out of 12 analysts across Wall Street view the stock positively, and its consensus price target of $14.63 suggests more than 200% in upside, significantly higher than CMPS.
A Potential Generalized Anxiety Disorder Treatment and Strong Analyst Support
Definium Therapeutics Inc. (NASDAQ: DFTX), previously known as Mind Medicine, has also faced significant net losses in recent years, although the fact that it ended 2025 with $258 million in cash and equivalents does buy it some much-needed time to move ahead with its MM120, a drug candidate for generalized anxiety disorder. Like both of the drugs above, MM120 has a potential addressable market that is colossal, and successfully commercializing the treatment could turn Definium from a speculative play into a dominant player in the biopharma field.
DFTX shares have only risen by about a quarter in the last month amid the news about the executive order, but analysts are more optimistic about this stock than either of the others above. It has 14 Buy ratings and only a single Sell, with forecasts of about 70% upside potential.
If all of the companies above seem too much of a risk, even after the recent push to accelerate the approval timeline for psychedelic drugs, investors might want to build diversified exposure to the industry with a niche exchange-traded fund like the AdvisorShares Psychedelics ETF (NYSEARCA: PSIL). This fund is actively managed, which likely contributes to its high expense ratio of 1%, but it provides ready-made access to about two dozen companies in the space. This can position investors to benefit when any of those firms experiences a big breakthrough—and can insulate when trial results don’t turn out as hoped. PSIL also offers a compelling dividend yield around 8.5% to further sweeten the deal.
Ad InvestorPlace
“Golden Dawn”: the code name that should be on every investor’s radar
“Golden Dawn”: the code name that should be on every investor’s radarWatch Louis Navellier’s Free Golden Dawn Presentation And Get The Ticker
Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales Tank
Homebuilders have been going through a rough patch as of late. Across top homebuilding stocks, analysts expected revenues and earnings to fall considerably in Q1 2026, and this is exactly what happened.
For over a year, stocks in this industry have been range-bound. The SPDR S&P Homebuilders ETF (NYSEARCA: XHB) is a commonly used proxy for this industry, tracking the performance of over 30 homebuilders or housing-related stocks. The fund has delivered an approximate total return of just 5% since the start of 2025. With interest rates still relatively high and housing affordability low, stocks in this space have struggled to gain much momentum.
Three of the top U.S. homebuilders just reported earnings; here’s how they stacked up and what it signals about the industry going forward.
Pulte’s EPS Falls 30%, Analysts Point to Moderate Upside
Pulte Group (NYSE: PHM) is one of the more diversified U.S. homebuilders targeting a balanced mix of market segments. In Q1, 38% of the company’s sales came from first-time buyers, while “move-up” buyers accounted for 39%. Its “active adult” buyer group, which includes sales in 55+ communities, accounted for 23% of sales.
Pulte saw its sales fall by 12% year over year (YOY) to $3.41 billion, essentially in line with estimates.
The significant decline came even as the company offered much greater incentives to home buyers. This led to a substantial 310 basis point compression in gross home sales margin.
In turn, adjusted earnings per share (EPS) tanked by just over 30% to $1.79, 1 cent short of estimates. The company’s new orders grew moderately by 3% YOY, similar to the 4% increase seen in Q4 2025, but Pulte did not change its guidance for the full year.
Still, Pulte saw a modest 2.4% gain after its report, indicating that the results were better than some investors had feared.
Several analysts tracked by MarketBeat raised their price targets after the report, with updates averaging around $147. This figure implies healthy upside in shares and is slightly above the MarketBeat consensus price target of around $141.
D.R. Horton Outperforms Against Low Expectations, Targets Spread
Homebuilding behemoth D.R. Horton (NYSE: DHI)was a clear standout. The company, which focuses on first-time home buyers, posted revenue of $7.56 billion. This marked a moderate 2% YOY drop, roughly in line with expectations and by far the best figure among this group. The firm also posted a solid bottom-line beat, with adjusted EPS of $2.24 versus estimates of $2.15. The figure fell by 13% YOY.
Forward-looking metrics were particularly strong, with home orders rising by 11% YOY, the highest rate among these names. The company did slightly lower the top end of its full-year guidance to $34.5 billion, but its midpoint estimate of $34 billion still exceeded estimates.
D.R. Horton also saw considerable margin compression, with the firm’s adjusted home sales gross margin declining by 230 basis points to 19.7%. Overall, these results allowed DHI shares to soar by nearly 6% post-earnings.
The MarketBeat consensus price target near $169 implies only around 5% upside in shares. Notably, all analysts who issued updates after the report raised their price targets; however, updated targets averaged around $165. They also showed significant variance, ranging from $206 to $123. These figures imply upside of more than 25% and downside of more than 20%, respectively.
NVR: Sales Plummet, Order Growth Ticks Up
NVR (NYSE: NVR) sits more in the middle of the market, with its average home selling price coming in at $457,000 in Q1 2026. This was squarely between Pulte’s $542,000 average selling price and D.R. Horton’s $362,000, showing the differences in income among their respective customers.
The company saw its revenues take a 21.7% hit, falling to $1.91 billion. This significantly missed the estimates of $2.09 billion. EPS fell by 28.6% to $67.76, missing estimates of $79.97 by a wide margin. The company’s gross margin compression mirrored D.R. Horton, with the figure falling 230 basis points to 19.6%.
However, like the other two names, new orders saw a moderate increase, rising by 7%. This was an improvement over the 4% increase in the prior quarter. NVR’s average selling price remained flat YOY, while the metric fell by 3% at Pulte and 5% at D.R. Horton. Combined with rising orders, this is a positive sign for NVR, showing that the company isn’t compromising on price to drive demand. Notably, NVR does not provide forward guidance. NVR shares fell 4.7% following the results.
Multiple analysts dropped their targets after the report, with updates averaging approximately $7,465, moderately below the consensus target near $7,650. This updated average target implies just under 15% upside in shares.
Homebuilders Continue to Face a Difficult Environment
Earnings across these three names showed a trend: revenue and margin hits across the industry. D.R. Horton was a bright spot, with the lowest sales decline and the highest order growth. Encouragingly, orders rose across all names, but the industry is still in a rut. Price targets remain relatively subdued, but point to upside ahead, indicating a degree of optimism among the analyst community.
Fixed rates on 30-year mortgages briefly fell below 6% prior to the conflict in the Middle East. Rates have since risen back to 6.2%. A clear end to the conflict would be a meaningful positive for homebuilders, likely helping rates approach 6% again, improving demand.
Ad Banyan Hill Publishing
The REAL Reason Trump is Invading Iran
The REAL Reason Trump is Invading IranClick Here To Find Out What It Is.
| Contact Us
MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.
